![](http://www.biofronttherapeutics.com/uploadfile/202110/caf68e115ff544c.jpg)
![](http://www.biofronttherapeutics.com/uploadfile/202110/1555c6737fafeea.jpg)
With a strong team of biopharmaceutical veterans and adequate funding, BioFront
aims to identify disease drivers and develop first-in-class therapeutics through
profit-sharing partnerships with academic investigators.
With a strong team of biopharmaceutical veterans and adequate funding, BioFront aims to identify disease drivers and develop first-in-class therapeutics through profit-sharing partnerships with academic investigators.
A well-recognized leader in pharmaceutical R&D with>20 years of management experience in pharma/biotech industry(Tularik,Amgen,Lilly). Inventor of 37 patents granted by the US Patent Office, including Amgen's PCSK9 antibody for the treatment of cardiovascular disease (Rapatha®).
Comming soon
>20 years of medicinal chemistry experience in pharma/biotech industry (Lilly, PEG Bio) ; proven track record in leading cross-functional teams, managing CROs and delivering milestones for multiple projects. Contributed to the discovery of an HBV medicine Clevudine(Levovir®;).
30 years of pharmaceutical R&D experience, with broad expertise in inflammatory, immunological, metabolic and cardiovascular diseases. Contributor to 4 launched drugs (Singulair®, Arcoxia®, Vioxx®, Tredaptive®).
Our headquarters in Beijing is based in a newly constructed >4000m2 facility equipped with state-of-the-art chemistry and biology laboratory instruments, located in Zhongguancun Beilun Industrial Park, Haidian District.